<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940705-2-00168</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4703 -->  <!-- PJG ITAG l=81 g=1 f=1 --> Section III-B&hyph;3. Minor Modifications to Human Gene Transfer Experiments  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> A minor modification in a human gene transfer protocol is a modification that does  <!-- PJG 0012 frnewline --> not significantly alter the basic design of the protocol and that does not increase risk  <!-- PJG 0012 frnewline --> to human subjects or the environment. After approval has been obtained by the  <!-- PJG 0012 frnewline --> relevant Institutional Biosafety Committee and Institutional Review Board,  <!-- PJG 0012 frnewline --> NIH/ORDA will consider the change in consultation with the RAC Chair and one  <!-- PJG 0012 frnewline --> or more RAC members, as necessary. Submit minor modifications to the Office of  <!-- PJG 0012 frnewline --> Recombinant DNA Activities, National Institutes of Health, Building 31, Room  <!-- PJG 0012 frnewline --> 4B11, Bethesda, Maryland 20892, (301) 496&hyph;9838. The RAC Chair will provide a  <!-- PJG 0012 frnewline --> report on any such approvals at the next regularly scheduled RAC meeting.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=81 g=1 f=1 --> Section III-C. Experiments that Require Institutional Biosafety Committee  <!-- PJG 0012 frnewline --> Approval Before Initiation  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Prior to the initiation of an experiment that falls into this category, the Principal  <!-- PJG 0012 frnewline --> Investigator must submit a registration document to the Institutional Biosafety  <!-- PJG 0012 frnewline --> Committee which contains the following information: (i) The source(s) of DNA; (ii)  <!-- PJG 0012 frnewline --> the nature of the inserted DNA sequences; (iii) the host(s) and vector(s) to be used;  <!-- PJG 0012 frnewline --> (iv) if an attempt will be made to obtain expression of a foreign gene, and if so,  <!-- PJG 0012 frnewline --> indicate the protein that will be produced; and (v) the containment conditions that  <!-- PJG 0012 frnewline --> will be implemented as specified in the NIH Guidelines. For experiments in this  <!-- PJG 0012 frnewline --> category, the registration document shall be dated, signed by the Principal  <!-- PJG 0012 frnewline --> Investigator, and filed with the Institutional Biosafety Committee. The Institutional  <!-- PJG 0012 frnewline --> Biosafety Committee shall review and approve all experiments in this category prior  <!-- PJG 0012 frnewline --> to their initiation. Requests to decrease the level of containment specified for  <!-- PJG 0012 frnewline --> experiments in this category will be considered by NIH (see Section IV-C&hyph;1-b-(2)-(c)).  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=81 g=1 f=1 --> Section III-C&hyph;1. Experiments Using Human or Animal Pathogens (Class 2, Class 3,  <!-- PJG 0012 frnewline --> Class 4, or Class 5 Agents (see Section V-A) as Host-Vector Systems  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Section III-C&hyph;1-a. Experiments involving the introduction of recombinant DNA into  <!-- PJG 0012 frnewline --> Class 2 agents shall be conducted at Biosafety Level (BL) 2 containment.  <!-- PJG 0012 frnewline --> Experiments with such agents shall be conducted with whole animals at BL2 or  <!-- PJG 0012 frnewline --> BL2&hyph;N (Animals) containment.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Section III-C&hyph;1-b. Experiments involving the introduction of recombinant DNA into  <!-- PJG 0012 frnewline --> Class 3 agents shall be conducted at BL3 containment. Experiments with such  <!-- PJG 0012 frnewline --> agents shall be conducted with whole animals at BL3 or BL3&hyph;N containment.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Section III-C&hyph;1-c. Experiments involving the introduction of recombinant DNA into  <!-- PJG 0012 frnewline --> Class 4 agents shall be conducted at BL4 containment. Experiments with such  <!-- PJG 0012 frnewline --> agents shall be conducted with whole animals at BL4 or BL4&hyph;N containment.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Section III-C&hyph;1-d. Containment conditions for experiments involving the  <!-- PJG 0012 frnewline --> introduction of recombinant DNA into Class 5 agents shall be set on a case-by-case  <!-- PJG 0012 frnewline --> basis following NIH/ORDA review. A U.S. Department of Agriculture permit is  <!-- PJG 0012 frnewline --> required for work with Class 5 agents (see Sections V-R and V-T). Experiments  <!-- PJG 0012 frnewline --> with such agents shall be conducted with whole animals at BL4 or BL4&hyph;N  <!-- PJG 0012 frnewline --> containment.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=81 g=1 f=1 --> Section III-C&hyph;2. Experiments in Which DNA From Human or Animal Pathogens  <!-- PJG 0012 frnewline --> (Class 2, Class 3, Class 4, or Class 5 Agents (see Section V-A) is Cloned Into  <!-- PJG 0012 frnewline --> Nonpathogenic Prokaryotic or Lower Eukaryotic Host-Vector Systems  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Section III-C&hyph;2-a. Experiments in which DNA from Class 2 or Class 3 agents (see  <!-- PJG 0012 frnewline --> Section V-A) is transferred into nonpathogenic prokaryotes or lower eukaryotes may  <!-- PJG 0012 frnewline --> be performed under BL2 containment. Experiments in which DNA from Class 4  <!-- PJG 0012 frnewline --> agents is transferred into nonpathogenic prokaryotes or lower eukaryotes may be  <!-- PJG 0012 frnewline --> performed under BL2 containment after demonstration that only a totally and  <!-- PJG 0012 frnewline --> irreversibly defective fraction of the agent's genome is present in a given  <!-- PJG 0012 frnewline --> recombinant. In the absence of such a demonstration, BL4 containment shall be  <!-- PJG 0012 frnewline --> used. The Institutional Biosafety Committee may approve the specific lowering of  <!-- PJG 0012 frnewline --> containment for particular experiments to BL1. Many experiments in this category  <!-- PJG 0012 frnewline --> are exempt from the NIH Guidelines (see Section III-E). Experiments involving the  <!-- PJG 0012 frnewline --> formation of recombinant DNA for certain genes coding for molecules toxic for  <!-- PJG 0012 frnewline --> vertebrates require NIH/ORDA approval (see Section III-B&hyph;1) or shall be  <!-- PJG 0012 frnewline --> conducted under NIH specified conditions as described in Appendix F.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Section III-C&hyph;2-b. Containment conditions for experiments in which DNA from  <!-- PJG 0012 frnewline --> Class 5 agents is transferred into nonpathogenic prokaryotes or lower eukaryotes  <!-- PJG 0012 frnewline --> shall be determined by NIH/ORDA following a case-by-case review. A U.S.  <!-- PJG 0012 frnewline --> Department of Agriculture permit is required for work with Class 5 agents (see  <!-- PJG 0012 frnewline --> Sections V-R and V-T).  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=81 g=1 f=1 --> Section III-C&hyph;3. Experiments Involving the Use of Infectious Animal or Plant DNA  <!-- PJG 0012 frnewline --> or RNA Viruses or Defective Animal or Plant DNA or RNA Viruses in the Presence  <!-- PJG 0012 frnewline --> of Helper Virus in Tissue Culture Systems  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Caution: Special care should be used in the evaluation of containment levels for  <!-- PJG 0012 frnewline --> experiments which are likely to either enhance the pathogenicity (e.g., insertion of a  <!-- PJG 0012 frnewline --> host oncogene) or to extend the host range (e.g., introduction of novel control  <!-- PJG 0012 frnewline --> elements) of viral vectors under conditions that permit a productive infection. In  <!-- PJG 0012 frnewline --> such cases, serious consideration should be given to increasing physical containment  <!-- PJG 0012 frnewline --> by at least one level.  <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            